Metformin in COVID-19: clinical trials are needed to prove its benefits
Ir J Med Sci
.
2022 Dec;191(6):2641-2642.
doi: 10.1007/s11845-021-02869-9.
Epub 2022 Jan 8.
Authors
Chia Siang Kow
1
2
,
Dinesh Sangarran Ramachandram
3
,
Syed Shahzad Hasan
4
5
Affiliations
1
School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia. chiasiang_93@hotmail.com.
2
School of Pharmacy, Monash University Malaysia, Bandar Sunway, Subang Jaya, Selangor, Malaysia. chiasiang_93@hotmail.com.
3
School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.
4
School of Applied Sciences, University of Huddersfield, Huddersfield, UK.
5
School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia.
PMID:
34997410
PMCID:
PMC8741591
DOI:
10.1007/s11845-021-02869-9
No abstract available
Publication types
Letter
Comment
MeSH terms
COVID-19*
Diabetes Mellitus, Type 2* / drug therapy
Humans
Hypoglycemic Agents / therapeutic use
Metformin* / therapeutic use
Substances
Metformin
Hypoglycemic Agents